Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kamel Abraham

Pain Medicine Springfield, OH Medical Doctor

NPI 1891887048 CMS profile 131110

1117 E Home Rd, Springfield, OH 45503

Open in the dashboard

General payments

$1,518

122 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kamel Abraham of Springfield, OH is reported in the CMS Open Payments database as having received $1,518 across 122 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 40th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18 1
2020 General $249 15
2019 General $1,251 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kamel Abraham
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Kamel Abraham were reported at $18. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Kamel Abraham Pain Medicine median Middle half National median
2019 $1,251 $506 $144–$1,566 $163
2020 $249 $315 $96–$934 $114
2021 $0 $452 $134–$1,237 $132
2022 $0 $475 $124–$1,407 $149
2023 $0 $480 $136–$1,384 $160
2024 $0 $521 $164–$1,511 $164
2025 $18 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $273 42 payments
  2. Amgen Inc. $202 12 payments
  3. Collegium Pharmaceutical, Inc. $175 13 payments
  4. Boston Scientific Corporation $167 10 payments
  5. Lilly USA, LLC $128 9 payments
  6. Abbott Laboratories $116 3 payments
  7. Novartis Pharmaceuticals Corporation $106 8 payments
  8. Biodelivery Sciences International, Inc. $100 7 payments
  9. Scilex Pharmaceuticals Inc. $70 5 payments
  10. Daiichi Sankyo Inc. $68 4 payments
  11. Other $113 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,518 122 payments
Products named General payments · program years 2019–2025
  1. AIMOVIG $308 20 payments
  2. LYRICA $272 41 payments
  3. XTAMPZA $175 13 payments
  4. GENERAL PAIN MANAGEMENT $107 4 payments
  5. FLECTOR PATCH $92 13 payments
  6. EMGALITY $77 6 payments
  7. Quattrode Leads SCS Leads $74 1 payment
  8. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $70 5 payments
  9. BUNAVAIL 4.2 mg single pouch $69 5 payments
  10. BUNAVAIL 6.3 mg 30-count box $69 5 payments
  11. Other $618 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record